Concourse Financial Group Securities, Inc. Aligos Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$0.35 - $1.07 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.64 - $1.13 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.56 - $0.8 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.71 - $1.06 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.71 - $1.06 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.89 - $1.36 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.89 - $28.0 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.06 - $27.5 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.04 - $2.14 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.08 - $12.2 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$11.48 - $17.69 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$14.57 - $17.72 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$20.3 - $33.6 $0 - $0
Q1 2021 May 13, 2021	BUY	$19.1 - $34.94 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$13.2 - $32.74 $0 - $0

Others Institutions Holding ALGS

# of Institutions

Shares Held

227K

Call Options Held

Put Options Held

Black Rock Inc. New York, NY

227K
Shares

$9.49 Million
0.0% of portfolio

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account